Results 231 to 240 of about 6,642,537 (325)

Probabilistic decision-support framework for community resilience: Incorporating multi-hazards, infrastructure interdependencies, and resilience goals in a Bayesian network

open access: bronze, 2019
Sabarethinam Kameshwar   +6 more
openalex   +2 more sources

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

open access: yesMolecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He   +8 more
wiley   +1 more source

Malaria innovations: pursuing value in an evolving market

open access: yesThe Lancet Global Health, 2018
Debra ten Brink   +2 more
doaj   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

open access: yesMolecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson   +2 more
wiley   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

open access: yesMolecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia   +9 more
wiley   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Specialist physician perspectives on clinical decision support to address secondary vaccine hesitancy. [PDF]

open access: yesJ Allergy Clin Immunol Glob
Nemorin A   +5 more
europepmc   +1 more source

Personalized choice of the optimal revascularization strategy in patients with combined lesions of coronary and brachiocephalic arteries: results of testing an automated decision support system in clinical practice

open access: diamond, 2018
Р. С. Тарасов   +5 more
openalex   +1 more source

Home - About - Disclaimer - Privacy